X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES PANACEA BIOTECH VENUS REMEDIES/
PANACEA BIOTECH
 
P/E (TTM) x -9.2 -22.3 - View Chart
P/BV x 0.1 3.1 4.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   PANACEA BIOTECH
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
PANACEA BIOTECH
Mar-14
VENUS REMEDIES/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs143149 96.0%   
Low Rs6582 79.0%   
Sales per share (Unadj.) Rs324.284.1 385.3%  
Earnings per share (Unadj.) Rs6.4-18.3 -35.0%  
Cash flow per share (Unadj.) Rs40.6-6.7 -605.7%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs366.083.7 437.2%  
Shares outstanding (eoy) m12.3461.25 20.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.4 23.3%   
Avg P/E ratio x16.2-6.3 -256.9%  
P/CF ratio (eoy) x2.6-17.2 -14.9%  
Price / Book Value ratio x0.31.4 20.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,2827,074 18.1%   
No. of employees `0000.92.8 32.8%   
Total wages/salary Rs m2511,449 17.3%   
Avg. sales/employee Rs Th4,430.11,874.1 236.4%   
Avg. wages/employee Rs Th278.0527.0 52.7%   
Avg. net profit/employee Rs Th87.6-407.7 -21.5%   
INCOME DATA
Net Sales Rs m4,0005,154 77.6%  
Other income Rs m23100 22.7%   
Total revenues Rs m4,0235,254 76.6%   
Gross profit Rs m785-766 -102.4%  
Depreciation Rs m422711 59.3%   
Interest Rs m3441,503 22.9%   
Profit before tax Rs m42-2,881 -1.5%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m-3717 -220.2%   
Profit after tax Rs m79-1,121 -7.1%  
Gross profit margin %19.6-14.9 -131.9%  
Effective tax rate %-87.9-0.6 15,068.8%   
Net profit margin %2.0-21.8 -9.1%  
BALANCE SHEET DATA
Current assets Rs m2,6063,810 68.4%   
Current liabilities Rs m1,9808,365 23.7%   
Net working cap to sales %15.6-88.4 -17.7%  
Current ratio x1.30.5 288.9%  
Inventory Days Days128156 82.4%  
Debtors Days Days4367 64.2%  
Net fixed assets Rs m5,35314,480 37.0%   
Share capital Rs m12361 201.3%   
"Free" reserves Rs m4,393903 486.4%   
Net worth Rs m4,5165,127 88.1%   
Long term debt Rs m1,6185,832 27.7%   
Total assets Rs m8,29119,433 42.7%  
Interest coverage x1.1-0.9 -122.5%   
Debt to equity ratio x0.41.1 31.5%  
Sales to assets ratio x0.50.3 181.9%   
Return on assets %5.12.0 259.6%  
Return on equity %1.8-21.9 -8.0%  
Return on capital %6.33.6 173.0%  
Exports to sales %024.5 0.0%   
Imports to sales %18.410.2 180.8%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs m736525 140.3%   
Fx inflow Rs m01,539 0.0%   
Fx outflow Rs m736942 78.2%   
Net fx Rs m-736597 -123.3%   
CASH FLOW
From Operations Rs m997599 166.4%  
From Investments Rs m-461-438 105.3%  
From Financial Activity Rs m-571-303 188.7%  
Net Cashflow Rs m-35-141 24.8%  

Share Holding

Indian Promoters % 32.9 74.5 44.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 0.6 30.0%  
FIIs % 0.6 1.3 44.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 23.6 281.4%  
Shareholders   20,121 10,259 196.1%  
Pledged promoter(s) holding % 36.4 35.1 103.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT LTD.  GSK PHARMA  PLETHICO PHARMA  

Compare VENUS REMEDIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Green; Metal Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5%

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2%

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jun 20, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS